Advertisement
Singapore markets closed

  • Straits Times Index

    3,336.59
    +13.21 (+0.40%)
     

  • Nikkei

    38,487.90
    +433.77 (+1.14%)
     

  • Hang Seng

    18,079.61
    -150.58 (-0.83%)
     

  • FTSE 100

    8,275.38
    +44.33 (+0.54%)
     

  • Bitcoin USD

    67,506.69
    -994.70 (-1.45%)
     

  • CMC Crypto 200

    1,419.52
    -9.05 (-0.63%)
     

  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     

  • Dow

    38,686.32
    +574.84 (+1.51%)
     

  • Nasdaq

    16,735.02
    -2.06 (-0.01%)
     

  • Gold

    2,347.70
    -18.80 (-0.79%)
     

  • Crude Oil

    77.18
    -0.73 (-0.94%)
     

  • 10-Yr Bond

    4.5140
    -0.0400 (-0.88%)
     

  • FTSE Bursa Malaysia

    1,596.68
    -7.58 (-0.47%)
     

  • Jakarta Composite Index

    6,970.74
    -63.41 (-0.90%)
     

  • PSE Index

    6,433.10
    +61.35 (+0.96%)
     

Director Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX)

GuruFocus Research
·1-min read

On May 13, 2024, Steven Galson, a Director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 21,940 shares of the company, as reported in a recent SEC Filing. The transaction occurred at a price of $5.49 per share.

BioCryst Pharmaceuticals Inc focuses on the development and commercialization of treatments for rare diseases. The company's portfolio includes therapies for hereditary angioedema and other complement-mediated diseases.

Over the past year, the insider has bought a total of 21,940 shares and has not sold any shares. This recent acquisition aligns with a broader pattern of insider activity at the company, which includes 6 insider buys and 2 insider sells over the same timeframe.

ADVERTISEMENT

The stock's market cap stands at $1.257 billion as of the latest trading price. According to GF Value, the intrinsic value estimate for BioCryst Pharmaceuticals Inc is $17.29 per share, suggesting that the stock is currently undervalued with a price-to-GF-Value ratio of 0.32.

The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and expected future business outcomes.

Director Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX)
Director Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX)
Director Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX)
Director Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX)

This insider purchase could signal a positive outlook from the director regarding the company's future performance and valuation.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.